ML348 is primarily utilized in research settings to study the endocannabinoid system and its associated pathways. It functions as a selective inhibitor of the enzyme diacylglycerol lipase alpha (DAGLα), which plays a crucial role in the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG). By inhibiting DAGLα, ML348 helps researchers investigate the physiological and pathological roles of 2-AG in various biological processes, including neurotransmission, inflammation, and pain signaling. This compound is particularly valuable in preclinical studies aimed at understanding the therapeutic potential of modulating the endocannabinoid system for conditions such as chronic pain, neurodegenerative diseases, and inflammatory disorders. Its use contributes to the development of targeted therapies that could regulate endocannabinoid levels without affecting other lipid pathways.